To Evaluate the Dose-response Effects of a Defined Volume of Physical Exercise on the Change of Peripheral Biomarkers, Clinical Response and Brain Connectivity in Parkinson's Disease: a Prospective, Observational, Cohort Pilot Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-02-11

Study Completion Date

2028-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, observational, cohort pilot study of standardize volume of aerobic exercise on changes in BDNF concentration at 4-weeks of exercise training among Parkinson disease patients.

Thirty (N=30) participants will be consecutively enrolled and assigned to 2 groups: 1) Extensive Rehabilitation Group (exercise volume: 180 METs-min/week) or 2) Intensive Rehabilitation Group (exercise volume: 1350 METs-min/week).

The primary objective is to evaluate the dose-response effects of two different rehabilitation settings, characterized by different workload (measured as energy expenditure), on blood BDNF levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Movement Improves Brain Health and Cognition in Parkinson's Disease

NCT07299279

Parkinson Disease

RECRUITING NA

Study in Parkinson's Disease of Exercise

NCT01506479

Parkinson Disease

COMPLETED NA

Physical Training Induced Plasticity of Motor Control Mechanisms in Parkinson's Disease Patients

NCT03753503

Parkinson Disease Physical Activity

COMPLETED NA

Parkinson's Research In Metagenomic Early Stage Biomarkers

NCT07097103

Parkinson's Disease (PD)

NOT_YET_RECRUITING NA

Cognitive, Affective, and Motor Effects of Tangotherapy in Parkinson's Disease

NCT05904171

Parkinson Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This pilot observational study will evaluate the dose-response relationship between the volume of exercise, measured as METs-minutes/week, of two different rehabilitation settings to quantify the change in BDNF concentration in PD patients.

The study will also compare the changes induced by extensive and intensive rehabilitation settings in other neurotrophic factors and peripheral biomarkers, on motor and non-motor symptoms, kinematic parameters of gait, cognitive function, quality of life and the changes in cortical activity assessed with electroencephalogram (EEG) and in brain connectivity by functional magnetic resonance imaging (fMRI).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Extensive Rehabilitation Group

PD patients of Extensive Group will perform a 45-minutes daily session of low-intensity aerobic exercise of 2-3 METs (37%-45% VO 2max ; 57-63% HR max) twice a week, for a 4-weeks period. Exercise volume: 180 METs-minutes/week

Aerobic exercise

Intervention Type BEHAVIORAL

Standardized volume of aerobic exercise, measured as METs-minutes/week

Intensive Rehabilitation Group

PD patients of Intensive Rehabilitation Group will exercise for 45 minutes daily at high-intensity aerobic training of 6-8.8 METs (46-91% VO2max ; 76-95% HRmax), five days per week, for 4-weeks period. Exercise volume:1350 METs-minutes/week

Aerobic exercise

Intervention Type BEHAVIORAL

Standardized volume of aerobic exercise, measured as METs-minutes/week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aerobic exercise

Standardized volume of aerobic exercise, measured as METs-minutes/week

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank
* Aged between 30 and 80 years
* Disease stage II-III in "ON" phase according to modified Hoehn and Yahr (H\&Y)
* Having no severe cognitive impairment:

* Mini-Mental State Examination-MMSE ≥24
* Montreal Cognitive Assessment - MoCA ≥ 17/30
* Under stable dopaminergic pharmacological treatment
* Motor condition that permits to execute 6-Minutes Walking Test (6MWT)
* Willing to participate in the study, understand the procedures and sign the informed consent.

Exclusion Criteria

* Diagnosis of neurological disorders not related to Parkinson's disease
* Musculoskeletal diseases that could impair gait and execution of exercise program
* Presence of known cardiovascular disease that can compromise the performance required by the protocol
* Presence of diabetes or other metabolic and endocrine disease
* Uncontrolled hypertension (resting blood pressure \>150/90 mmHg)
* Individuals with orthostatic hypotension and systolic pressure in feet below 100 will be excluded. Orthostatic hypotension (OH) is a reduction in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 minutes of standing.
* Hypo- or hyperthyroidism (TSH \<0.5 or \>5.0 mU/L), abnormal liver function (AST or ALT more than 2 times the upper limit of normal, ULN), alteration of kidney function.
* Values of complete blood test out of range and abnormal value clinically significant as per clinical judgment.
* Recent use of psychotropic drugs (e.g. anxiolytics, hypnotics, benzodiazepines, antidepressants) in which the dosage was not stable for 28 days before screening
* Severe disease (requiring systemic treatment and/or hospitalization) in the last 4 weeks.
* Any other clinically significant medical condition, psychiatric condition, drug or alcohol abuse, laboratory evaluation or abnormality that, in the opinion of the investigators, would interfere with the subject's ability to participate in the study.
* Beck Depression Inventory II (BDI) score \> 28, indicating a severe depression that precludes the ability to exercise.
* (Only for women) State of pregnancy.
* Other disorders, injuries, diseases or conditions that may interfere with the ability to perform exercises (e.g. history of stroke, breathing problems, traumatic brain injury, orthopaedic injury or neuromuscular disease).

Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No